Jove
Visualize
Contact Us

Related Concept Videos

Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

8.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
8.9K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

4.2K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
4.2K
Protein-protein Interfaces02:04

Protein-protein Interfaces

14.2K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
14.2K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

6.8K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
6.8K
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

769
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
769
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.4K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ToxiSpecies: Task-Aware Meta-Learning for Cross-Species Modeling of Acute Chemical Toxicity under Distribution Shift.

Journal of chemical information and modeling·2026
Same author

Generative pretraining for drug molecule design with bidirectional structure-property optimization.

Communications chemistry·2026
Same author

Genome-guided generative adversarial learning enables nanopore adaptive sequencing.

Nature communications·2026
Same author

ToxiGuard: an AOP-guided mechanistically interpretable framework for multi-organ toxicity prediction.

Archives of toxicology·2026
Same author

Large-scale data-driven pre-trained DNA models enhance performance across diverse genomics tasks.

Nature communications·2026
Same author

A Multitask Active Learning Framework with Probabilistic Modeling for Multi-Species Acute Toxicity Prediction.

Molecules (Basel, Switzerland)·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Nov 16, 2025

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

3.2K

Drug-Target Interaction Prediction Based on Adversarial Bayesian Personalized Ranking.

Yihua Ye1, Yuqi Wen2, Zhongnan Zhang1

  • 1School of Informatics, Xiamen University, Xiamen 361005, China.

Biomed Research International
|February 25, 2021
PubMed
Summary

This study introduces AdvB-DTI, a novel model for predicting drug-target interactions (DTIs) by integrating expression profiles with matrix factorization. The new method improves prediction accuracy for drug repositioning.

More Related Videos

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

683
Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions
06:50

Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions

Published on: January 26, 2024

2.2K

Related Experiment Videos

Last Updated: Nov 16, 2025

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

3.2K
Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

683
Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions
06:50

Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions

Published on: January 26, 2024

2.2K

Area of Science:

  • Computational biology
  • Pharmacology
  • Bioinformatics

Background:

  • Drug-target interaction (DTI) prediction is crucial for drug repositioning.
  • Existing matrix factorization methods for DTI prediction often overlook drug and target expression profiles, limiting performance.
  • Data sparsity is a significant challenge in DTI prediction.

Purpose of the Study:

  • To propose a novel DTI prediction model, AdvB-DTI, that incorporates drug and target expression profiles.
  • To enhance DTI prediction performance by integrating expression data with matrix factorization and adversarial Bayesian personalized ranking.
  • To address the data sparsity issue in DTI prediction.

Main Methods:

  • Generating ternary partial order relationships from known drug-target relationships.
  • Training latent factor matrices using Adversarial Bayesian Personalized Ranking (AdvB-PIR) with expression profile features.
  • Improving matrix factorization by incorporating drug and target expression profiles.
  • Calculating drug-target pair scores via inner product of latent factors for ranking-based DTI prediction.
  • Introducing perturbation factors for model robustness.

Main Results:

  • The AdvB-DTI model effectively integrates drug and target expression profiles into the DTI prediction framework.
  • The model leverages the 'learning to rank' approach to mitigate data sparsity.
  • Experimental results demonstrate superior DTI prediction performance compared to existing methods.
  • The inclusion of perturbation factors enhances model robustness.

Conclusions:

  • AdvB-DTI offers an effective approach for DTI prediction by utilizing expression profiles and advanced ranking techniques.
  • The model shows significant potential for improving drug repositioning strategies.
  • The proposed method provides a robust and accurate solution for the challenging problem of DTI prediction.